The VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis
暂无分享,去创建一个
D. Berman | T. Henry | P. Shah | R. Benza | C. Gibson | J. Willerson | A. Rundle | A. Bajamonde | B. Annex | G. McKendall | John J. Lopez | M. Azrin | F. Giordano | J. Fine | E. Mccluskey | E. McCluskey | John J. Lopez
[1] R. Hendel,et al. Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial Ischemia , 2002, Circulation.
[2] C. Grines,et al. Angiogenic Gene Therapy (AGENT) Trial in Patients With Stable Angina Pectoris , 2002, Circulation.
[3] T. Henry,et al. Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial , 2002, Circulation.
[4] J. Pearlman,et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. , 2000, Journal of the American College of Cardiology.
[5] Henry Td,et al. Review of Preclinical and Clinical Results with Vascular Endothelial Growth Factors for Therapeutic Angiogenesis. , 2000 .
[6] R. Hendel,et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. , 2000, Circulation.
[7] J. Pearlman,et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. , 1999, Circulation.
[8] J. Isner,et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. , 1999, The Annals of thoracic surgery.
[9] M. Post,et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. , 1999, Circulation.
[10] N. Ferrara. Vascular endothelial growth factor: molecular and biological aspects. , 1999, Current topics in microbiology and immunology.
[11] J. Pearlman,et al. VEGF administration in chronic myocardial ischemia in pigs. , 1998, Cardiovascular research.
[12] K Walsh,et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. , 1998, Circulation.
[13] B. V. von Specht,et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. , 1998, Circulation.
[14] R. Hendel,et al. Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial , 1998 .
[15] B. Keyt,et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. , 1996, The Journal of surgical research.
[16] J. Pearlman,et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. , 1996, The American journal of physiology.
[17] J. Pearlman,et al. Magnetic resonance mapping demonstrates benefits of VEGF–induced myocardial angiogenesis , 1995, Nature Medicine.
[18] J. Spertus,et al. Monitoring the quality of life in patients with coronary artery disease. , 1994, The American journal of cardiology.
[19] S. Epstein,et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. , 1994, Circulation.